BUZZ - Driven by expected benefits from FDA and Medicare, TD Cowen raises Grail's target price by more than double, sending the company's stock soaring.

October 13 - ** Grail (GRAL.O) shares rose over 2% to $140.53

** TD Cowen raised the target price for this cancer detection company from $88 to $180 — a 31% upside from the previous day's closing price; maintains "Buy" rating

** After the FDA advisory committee meeting, the broker increased the probability of Grail's Galleri early cancer detection kit receiving FDA approval from 75% to 95%, with a decision expected in the first quarter of 2027

** Positive Medicare reimbursement decision expected in the first half of 2028

** Out of 12 brokers, 5 gave GRAL a "Buy" or higher rating, and 7 gave a "Hold" rating; the median target price is $120 — according to data compiled by LSEG

** Accounting for the day's price change, the stock has risen about 64% year-to-date

(To assist non-English speakers, Reuters has automated its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss arising from the use of automated translation features.)